4//SEC Filing
Jovan-Embiricos Morana 4
Accession 0001104659-22-086343
CIK 0001789972other
Filed
Aug 3, 8:00 PM ET
Accepted
Aug 4, 9:01 PM ET
Size
22.6 KB
Accession
0001104659-22-086343
Insider Transaction Report
Form 4
F2 Vision SCS
10% Owner
Transactions
- Sale
Common Stock
2022-08-03$14.24/sh−19,129$272,334→ 1,281,952 total - Sale
Common Stock
2022-08-02$14.10/sh−4,792$67,554→ 1,301,081 total - Sale
Common Stock
2022-08-04$14.31/sh−25,989$371,788→ 1,255,963 total
Holdings
- 537,392(indirect: By F2 Bioscience I 2017 Ltd.)
Common Stock
- 71,599(indirect: By LLC)
Common Stock
- 104,762(indirect: By LLC)
Common Stock
- 325,333(indirect: By F2 MG Ltd.)
Common Stock
- 622,175(indirect: By LLC)
Common Stock
- 214,798(indirect: By LLC)
Common Stock
- 207,803(indirect: By Morana Jovan-Embiricos)
Common Stock
- 1,136,525(indirect: By Globeways Holdings Ltd.)
Common Stock
Jovan-Embiricos Morana
Director10% Owner
Transactions
- Sale
Common Stock
2022-08-03$14.24/sh−19,129$272,334→ 1,281,952 total - Sale
Common Stock
2022-08-04$14.31/sh−25,989$371,788→ 1,255,963 total - Sale
Common Stock
2022-08-02$14.10/sh−4,792$67,554→ 1,301,081 total
Holdings
- 1,136,525(indirect: By Globeways Holdings Ltd.)
Common Stock
- 325,333(indirect: By F2 MG Ltd.)
Common Stock
- 71,599(indirect: By LLC)
Common Stock
- 104,762(indirect: By LLC)
Common Stock
- 537,392(indirect: By F2 Bioscience I 2017 Ltd.)
Common Stock
- 214,798(indirect: By LLC)
Common Stock
- 207,803(indirect: By Morana Jovan-Embiricos)
Common Stock
- 622,175(indirect: By LLC)
Common Stock
Footnotes (12)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F10]These securities are owned directly by F2 MC, LLC ("F2 MC"). Globeways II is the appointed manager of F2 MC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F11]These securities are owned directly by F2 GC LLC ("F2 GC"). Globeways II is the appointed manager of F2 GC. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F12]These securities are owned directly by Dr. Jovan-Embiricos. Each of the Reporting Persons except for Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F2]These securities are owned directly by F2 Vision SCS ("F2 Vision"). F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]These securities are owned directly by Globeways Holdings Limited ("Globeways"). Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F6]These securities are owned directly by F2 Bioscience I 2017 Limited ("F2 Bioscience 2017"). Globeways is the appointed manager of F2 Bioscience 2017. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F7]These securities are owned directly by F2 MG Limited ("F2 MG"). Globeways is the appointed manager of F2 MG. Dr. Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F8]These securities are owned directly by F2-TPO Investments, LLC ("F2-TPO"). Globeways Holdings II Limited ("Globeways II") is the appointed manager of F2-TPO. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F9]These securities are owned directly by F2 Bio TD, LLC ("F2 Bio"). Globeways II is the appointed manager of F2 Bio. Dr. Jovan-Embiricos is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Documents
Issuer
Cullinan Oncology, Inc.
CIK 0001789972
Entity typeother
Related Parties
1- filerCIK 0001575745
Filing Metadata
- Form type
- 4
- Filed
- Aug 3, 8:00 PM ET
- Accepted
- Aug 4, 9:01 PM ET
- Size
- 22.6 KB